1541 related articles for article (PubMed ID: 17159189)
21. Change in Pattern of HER2 Fluorescent in Situ Hybridization (FISH) Results in Breast Cancers Submitted for FISH Testing: Experience of a Reference Laboratory Using US Food and Drug Administration Criteria and American Society of Clinical Oncology and College of American Pathologists Guidelines.
Shah MV; Wiktor AE; Meyer RG; Tenner KS; Ballman KV; Green SJ; Sukov WR; Ketterling RP; Perez EA; Jenkins RB
J Clin Oncol; 2016 Oct; 34(29):3502-3510. PubMed ID: 27458302
[TBL] [Abstract][Full Text] [Related]
22. HER2 Testing for Breast Cancer in the Genomics Laboratory: A Sea Change for Fluorescence In Situ Hybridization.
Geiersbach KB; Sill DR; Meyer RG; Yuhas JA; Sukov WR; Mounajjed T; Carter JM; Jenkins RB; Chen B
Arch Pathol Lab Med; 2021 Jul; 145(7):883-886. PubMed ID: 33112955
[TBL] [Abstract][Full Text] [Related]
23. HER2 double-equivocal breast cancer in Chinese patients: a high concordance of HER2 status between different blocks from the same tumor.
Liu Y; Wu S; Shi X; Luo Y; Pang J; Wang C; Mao F; Liang Z; Zeng X
Breast Cancer Res Treat; 2019 Nov; 178(2):275-281. PubMed ID: 31388934
[TBL] [Abstract][Full Text] [Related]
24. Her2/neu Status Determination in Breast Cancer: A Single Institutional Experience Using a Dual-Testing Approach With Immunohistochemistry and Fluorescence In Situ Hybridization.
Solomon JP; Dell'Aquila M; Fadare O; Hasteh F
Am J Clin Pathol; 2017 Apr; 147(4):432-437. PubMed ID: 28340220
[TBL] [Abstract][Full Text] [Related]
25. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.
Hammond ME; Hayes DF; Dowsett M; Allred DC; Hagerty KL; Badve S; Fitzgibbons PL; Francis G; Goldstein NS; Hayes M; Hicks DG; Lester S; Love R; Mangu PB; McShane L; Miller K; Osborne CK; Paik S; Perlmutter J; Rhodes A; Sasano H; Schwartz JN; Sweep FC; Taube S; Torlakovic EE; Valenstein P; Viale G; Visscher D; Wheeler T; Williams RB; Wittliff JL; Wolff AC
Arch Pathol Lab Med; 2010 Jun; 134(6):907-22. PubMed ID: 20524868
[TBL] [Abstract][Full Text] [Related]
26. Silver in situ hybridization (SISH) for determination of HER2 gene status in breast carcinoma: comparison with FISH and assessment of interobserver reproducibility.
Papouchado BG; Myles J; Lloyd RV; Stoler M; Oliveira AM; Downs-Kelly E; Morey A; Bilous M; Nagle R; Prescott N; Wang L; Dragovich L; McElhinny A; Garcia CF; Ranger-Moore J; Free H; Powell W; Loftus M; Pettay J; Gaire F; Roberts C; Dietel M; Roche P; Grogan T; Tubbs R
Am J Surg Pathol; 2010 Jun; 34(6):767-76. PubMed ID: 20421783
[TBL] [Abstract][Full Text] [Related]
27. HER2 FISH classification of equivocal HER2 IHC breast cancers with use of the 2013 ASCO/CAP practice guideline.
Fan YS; Casas CE; Peng J; Watkins M; Fan L; Chapman J; Ikpatt OF; Gomez C; Zhao W; Reis IM
Breast Cancer Res Treat; 2016 Feb; 155(3):457-62. PubMed ID: 26895325
[TBL] [Abstract][Full Text] [Related]
28. Impact of the updated 2018 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines on Human Epidermal Growth Factor Receptor 2 (HER2) gene testing in invasive breast cancers: A single center study.
Lim TH; Lim AST; Tien SL; Tan PH
Ann Diagn Pathol; 2022 Jun; 58():151935. PubMed ID: 35313158
[TBL] [Abstract][Full Text] [Related]
29. Impact of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Updates on HER2 Assessment in Breast Cancer With Equivocal HER2 Immunohistochemistry Results With Focus on Cases With
Hoda RS; Brogi E; Xu J; Ventura K; Ross DS; Dang C; Robson M; Norton L; Morrow M; Wen HY
Arch Pathol Lab Med; 2020 May; 144(5):597-601. PubMed ID: 31647316
[TBL] [Abstract][Full Text] [Related]
30. Current issues in ER and HER2 testing by IHC in breast cancer.
Gown AM
Mod Pathol; 2008 May; 21 Suppl 2():S8-S15. PubMed ID: 18437174
[TBL] [Abstract][Full Text] [Related]
31. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-College of American Pathologists Guideline Update.
Wolff AC; Somerfield MR; Dowsett M; Hammond MEH; Hayes DF; McShane LM; Saphner TJ; Spears PA; Allison KH
J Clin Oncol; 2023 Aug; 41(22):3867-3872. PubMed ID: 37284804
[TBL] [Abstract][Full Text] [Related]
32. Impact of the 2013 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 (HER2) testing of invasive breast carcinoma: a focus on tumours assessed as 'equivocal' for HER2 gene amplification by fluorescence in-situ hybridization.
Bethune GC; Veldhuijzen van Zanten D; MacIntosh RF; Rayson D; Younis T; Thompson K; Barnes PJ
Histopathology; 2015 Dec; 67(6):880-7. PubMed ID: 25913507
[TBL] [Abstract][Full Text] [Related]
33. Comparative Analysis of Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer According to 2007 and 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations.
Hanna WM; Slodkowska E; Lu FI; Nafisi H; Nofech-Mozes S
J Clin Oncol; 2017 Sep; 35(26):3039-3045. PubMed ID: 28445098
[TBL] [Abstract][Full Text] [Related]
34. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version).
Hammond ME; Hayes DF; Dowsett M; Allred DC; Hagerty KL; Badve S; Fitzgibbons PL; Francis G; Goldstein NS; Hayes M; Hicks DG; Lester S; Love R; Mangu PB; McShane L; Miller K; Osborne CK; Paik S; Perlmutter J; Rhodes A; Sasano H; Schwartz JN; Sweep FC; Taube S; Torlakovic EE; Valenstein P; Viale G; Visscher D; Wheeler T; Williams RB; Wittliff JL; Wolff AC; ;
Arch Pathol Lab Med; 2010 Jul; 134(7):e48-72. PubMed ID: 20586616
[TBL] [Abstract][Full Text] [Related]
35. [Assessment of HER2 gene amplification in breast cancer: a comparison of dual-color in-situ hybridization and fluorescence in-situ hybridization].
Xu Y; Yang W; Yang F; Lu Y; Cai X; Zhou X
Zhonghua Bing Li Xue Za Zhi; 2014 Apr; 43(4):226-30. PubMed ID: 24915811
[TBL] [Abstract][Full Text] [Related]
36. HER2 equivocal breast cancer that is positive by alternative probe HER2 FISH are classified as HER2 negative by Oncotype DX.
Tozbikian GH; Zynger DL
Breast J; 2018 Jul; 24(4):535-540. PubMed ID: 29498449
[TBL] [Abstract][Full Text] [Related]
37. The Impact of Partial Weak Staining in Normal Breast Epithelium on the Reliability of Immunohistochemistry Results in HercepTest-positive Breast Cancer.
Farra C; Fedda F; Tfayli A; Tawil A; Zaatari G; Ashkar H; Issa G; Boulos F
Clin Breast Cancer; 2019 Oct; 19(5):340-344. PubMed ID: 31213407
[TBL] [Abstract][Full Text] [Related]
38. HER2 testing in breast cancer: NCCN Task Force report and recommendations.
Carlson RW; Moench SJ; Hammond ME; Perez EA; Burstein HJ; Allred DC; Vogel CL; Goldstein LJ; Somlo G; Gradishar WJ; Hudis CA; Jahanzeb M; Stark A; Wolff AC; Press MF; Winer EP; Paik S; Ljung BM;
J Natl Compr Canc Netw; 2006 Jul; 4 Suppl 3():S1-22; quiz S23-4. PubMed ID: 16813731
[TBL] [Abstract][Full Text] [Related]
39. Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines.
Press MF; Seoane JA; Curtis C; Quinaux E; Guzman R; Sauter G; Eiermann W; Mackey JR; Robert N; Pienkowski T; Crown J; Martin M; Valero V; Bee V; Ma Y; Villalobos I; Slamon DJ
JAMA Oncol; 2019 Mar; 5(3):366-375. PubMed ID: 30520947
[TBL] [Abstract][Full Text] [Related]
40. Impact of the 2013 ASCO/CAP HER2 Guideline Updates at an Academic Medical Center That Performs Primary HER2 FISH Testing: Increase in Equivocal Results and Utility of Reflex Immunohistochemistry.
Muller KE; Marotti JD; Memoli VA; Wells WA; Tafe LJ
Am J Clin Pathol; 2015 Aug; 144(2):247-52. PubMed ID: 26185309
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]